Janux Therapeutics, Inc. (JANX)

US — Healthcare Sector
Peers: MLYS  ELYM  ANEB  RZLT  KROS  FENC  EWTX  HRMY  MOLN  MNOV  CSBR  CYT  AVTE  ADAG  ACRV  ANTX 

Automate Your Wheel Strategy on JANX

With Tiblio's Option Bot, you can configure your own wheel strategy including JANX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol JANX
  • Rev/Share 0.1511
  • Book/Share 16.3852
  • PB 1.4525
  • Debt/Equity 0.0223
  • CurrentRatio 58.4698
  • ROIC -0.1097

 

  • MktCap 1408369760.0
  • FreeCF/Share -0.7531
  • PFCF -30.2654
  • PE -18.917
  • Debt/Assets 0.0215
  • DivYield 0
  • ROE -0.0929

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Reiterated JANX BTIG Research -- Buy $82 $100 Dec. 3, 2024
Reiterated JANX H.C. Wainwright -- Buy $63 $70 Dec. 3, 2024
Initiation JANX Stifel -- Buy -- $70 Sept. 6, 2024

News

About Janux Therapeutics, Inc. (JANX)

  • IPO Date 2021-06-11
  • Website https://www.januxrx.com
  • Industry Biotechnology
  • CEO Dr. David Alan Campbell Ph.D.
  • Employees 91

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.